Craig Stephens appointed SVP at Evergreen Re
STUART, Fla. Evergreen Re will get a new senior vice president, chief executive officer Charles Crispin has said.
Craig Stephens will be in charge of strategic development and management of the firm’s pharmacy consulting division, Evergreen Rx. Evergreen Re, a managed care reinsurance broker, is a division of Brown & Brown.
Stephens previously worked as senior vice president of marketing and innovation for Walgreens Health Services. Before that, he was vice president for industry relations and networks for UnitedHealth Group and also worked for GlaxoSmithKline for eight years.
Glue-like bacterial sugar could lead to vaccine
LONDON A study has found that when manipulated with chemicals, a sugar that drug-resistant bacteria secrete triggered an immune response in animals.
The study, presented last week at the Dublin, Ireland, meeting of the Society for General Microbiology used a glue-like sugar that bacteria produce to protect themselves from antibiotics called PNAG.
PNAG alone does not produce an immune response in most people and animals, but the researchers, from the Harvard Medical School, hope that formulations of it do.
FDA announces likely delay on Novo Nordisk diabetes drug
WASHINGTON The Food and Drug Administration has announced that it will be unable to meet the user fee deadline for a timely approval of Novo Nordisk’s drug liragludite.
The FDA will not be able to make an approvability decision until March 23 for the drug, a treatment for Type 2 diabetes. Novo Nordisk had submitted an approval application for the drug on May 23.
The standard review period for FDA action on approval applications is 10 months. Because the agency’s advisory committee meeting will take place shortly before March 23, however, its decision will probably be delayed by a further two months, the company said.